These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35438536)

  • 21. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
    Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral and latent reservoir persistence in HIV-1-infected patients on therapy.
    Kim H; Perelson AS
    PLoS Comput Biol; 2006 Oct; 2(10):e135. PubMed ID: 17040122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
    Shehu-Xhilaga M; Tachedjian G; Crowe SM; Kedzierska K
    Curr Med Chem; 2005; 12(15):1705-19. PubMed ID: 16029143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
    Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
    J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.
    Kaplan AH; Manchester M; Swanstrom R
    J Virol; 1994 Oct; 68(10):6782-6. PubMed ID: 8084015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CARD8 is an inflammasome sensor for HIV-1 protease activity.
    Wang Q; Gao H; Clark KM; Mugisha CS; Davis K; Tang JP; Harlan GH; DeSelm CJ; Presti RM; Kutluay SB; Shan L
    Science; 2021 Mar; 371(6535):. PubMed ID: 33542150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips.
    Rong L; Perelson AS
    Math Biosci; 2009 Jan; 217(1):77-87. PubMed ID: 18977369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.
    Natesampillai S; Nie Z; Cummins NW; Jochmans D; Bren GD; Angel JB; Badley AD
    PLoS Pathog; 2010 Nov; 6(11):e1001213. PubMed ID: 21124822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro.
    McPhee F; Caldera PS; Bemis GW; McDonagh AF; Kuntz ID; Craik CS
    Biochem J; 1996 Dec; 320 ( Pt 2)(Pt 2):681-6. PubMed ID: 8973584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
    Dashti A; Waller C; Mavigner M; Schoof N; Bar KJ; Shaw GM; Vanderford TH; Liang S; Lifson JD; Dunham RM; Ferrari G; Tuyishime M; Lam CK; Nordstrom JL; Margolis DM; Silvestri G; Chahroudi A
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV protease-mediated activation of sterically capped proteasome inhibitors and substrates.
    Buckley DL; Corson TW; Aberle N; Crews CM
    J Am Chem Soc; 2011 Feb; 133(4):698-700. PubMed ID: 21186803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Immunodeficiency Virus Gag and protease: partners in resistance.
    Fun A; Wensing AM; Verheyen J; Nijhuis M
    Retrovirology; 2012 Aug; 9():63. PubMed ID: 22867298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
    López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
    Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility.
    Watanabe SM; Simon V; Durham ND; Kemp BR; Machihara S; Kemal KS; Shi B; Foley B; Li H; Chen BK; Weiser B; Burger H; Anastos K; Chen C; Carter CA
    Retrovirology; 2016 Sep; 13(1):64. PubMed ID: 27600154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.